Simple Pneumonia and Pleurisy with MCC DRG Reimbursement

Summary & Overview

Simple Pneumonia and Pleurisy with MCC: Inpatient Reimbursement Overview

DRG 193 addresses inpatient admissions for simple pneumonia and pleurisy accompanied by a Major Complication or Comorbidity, indicating higher clinical complexity. It matters for inpatient reimbursement because the Major Complication or Comorbidity status elevates the Diagnosis-Related Group assignment and typically increases Medicare payment to reflect greater resource utilization.

Simple Pneumonia and Pleurisy with MCCDRG Simple Pneumonia and Pleurisy with MCCDRG 193Diagnosis-Related GroupInpatient ReimbursementMedicarePulmonologyInfectious DiseaseHospital Medicine

DRG 193 Overview

DRG 193 covers inpatient admissions for simple pneumonia and pleurisy when a Major Complication or Comorbidity is present, reflecting cases with increased clinical complexity such as acute respiratory failure or severe sepsis. This Diagnosis-Related Group is important for Medicare payment because the presence of a Major Complication or Comorbidity typically triggers higher reimbursement to account for greater resource use and longer lengths of stay. Accurate documentation and coding of the Major Complication or Comorbidity directly affect payment assignment and hospital billing for these admissions. The DRG also guides case-mix measurement and hospital comparative metrics under Medicare payment systems.

National Payment Rates

Across commercial payers the observed rate range spans from about $13K (BCBS median) up to $49K (Anthem max), with payer medians clustering near $20K–$23K; the widest spread is seen with Anthem (min $390 to max $49K). See the table and chart below for payer-level percentiles and distribution details. Aetna, Cigna, Anthem, and BCBS show distinct percentile patterns reflecting differing negotiated rates.

Mean Rates by Payer — National — DRG 193

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s reimbursed amounts for DRG 193 range from roughly $7.5K at the low end to $56K at the high end across payers, with most payers clustering near a $20K mean while Cigna stands out around $33K. This wide range reflects a pronounced outlier in Cigna’s higher maximum and mean compared with the other state payers and with typical national levels. See the table and chart below for payer-specific distributions.

Key Insights for Alaska

Highest payer: Cigna (max $56K, mean $33K) — notably above other local payers.
Lowest payer: Anthem/Blue Cross Blue Shield (max $32K, mean $20K) — both share similar distributions and sit well below Cigna.
Meaningful deviation: Cigna’s mean ($33K) substantially exceeds the other Alaska payers’ means (~$20K), and is higher than the listed national averages, indicating a pronounced premium in the state for this DRG.

Clinical Trials

Acute antimicrobial strategy trials: randomized or pragmatic studies comparing different antibiotic regimens (choice, duration, or route of administration) in hospitalized adults with community-acquired pneumonia or pleurisy complicated by major comorbid conditions (for example, heart failure, chronic lung disease, or severe diabetes). These studies enroll patients at admission to evaluate time to clinical stability, length of stay, and in-hospital complication rates, helping determine which initial inpatient antimicrobial approaches lead to faster recovery and fewer complications. Findings are directly relevant to providers for bedside antibiotic selection and to payers because optimized regimens can shorten LOS and reduce use of escalation therapies and downstream costs.
Supportive care and respiratory management trials: comparative effectiveness or device studies examining oxygen delivery strategies, use of noninvasive ventilation, airway clearance techniques, or standardized protocols for early mobilization and pulmonary hygiene in patients hospitalized with pneumonia and pleurisy who have major comorbidities or physiologic instability. These trials typically focus on differences in need for ICU transfer, incidence of respiratory failure, length of stay, and readmission risk among subgroups such as elderly patients, those with COPD, or heart failure. Results inform inpatient care pathways and resource allocation decisions, guiding clinicians on which supportive interventions reduce complications and informing payers about interventions that may lower utilization of high-cost services.
Post-discharge outcomes and transitional care studies: cohort studies and randomized trials testing discharge planning interventions, early outpatient follow-up models, home health support, or hospitalization-to-home care bundles for survivors of pneumonia with significant comorbidities and an index hospitalization coded as Simple Pneumonia and Pleurisy with MCC. These studies measure 30-day readmission rates, post-discharge mortality, medication adherence, and functional recovery, often targeting older adults or patients with complex chronic conditions who are at high risk for readmission. This area is essential for providers to reduce avoidable returns and improve recovery, and for payers because effective transitional care can reduce costly readmissions and long post-acute service use.

Respiratory System Diagnosis with Ventilator Support >96 Hours: Inpatient Reimbursement Overview

164-MAJOR-CHEST-PROCEDURES-WITH-CC

Major Chest Procedures with CC: Inpatient Reimbursement Overview

197-INTERSTITIAL-LUNG-DISEASE-WITH-CC

Interstitial Lung Disease with CC: Inpatient Reimbursement Overview

178-RESPIRATORY-INFECTIONS-AND-INFLAMMATIONS-WITH-CC

Respiratory Infections and Inflammations with CC: Inpatient Reimbursement Overview

182-RESPIRATORY-NEOPLASMS-WITHOUT-CC-MCC

Respiratory Neoplasms without CC/MCC: Inpatient Reimbursement Overview

203-BRONCHITIS-AND-ASTHMA-WITHOUT-CC-MCC

Bronchitis and Asthma without CC/MCC: Inpatient Reimbursement Overview

205-OTHER-RESPIRATORY-SYSTEM-DIAGNOSES-WITH-MCC

Other Respiratory System Diagnoses with MCC: Inpatient Reimbursement Overview

195-SIMPLE-PNEUMONIA-AND-PLEURISY-WITHOUT-CC-MCC

Simple Pneumonia and Pleurisy without CC/MCC: Inpatient Reimbursement Overview

168-OTHER-RESPIRATORY-SYSTEM-O-R-PROCEDURES-WITHOUT-CC-MCC

Other Respiratory System O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

166-OTHER-RESPIRATORY-SYSTEM-O-R-PROCEDURES-WITH-MCC

Other Respiratory System O.R. Procedures with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 40

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$11K	$57K	$9.4K	130K